CompletedPhase 2

Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer

United States17 participantsStarted 2018-02-22

Plain-language summary

This pilot clinical trial studies how well gallium Ga 68-DOTATATE positron emission tomography (PET)/computed tomography (CT) works in treating patients with castration resistant prostate cancer that has spread to other placed in the body. Gallium Ga 68-DOTATATE PET/CT may help doctors to identify those patients with early neuroendocrine transdifferentiation and who are at greater risk for poor outcomes.

Who can participate

Age range18 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with metastatic castration resistant prostate carcinoma with skeletal, visceral and/or nodal involvement * Ability to lie still for PET scanning * Patients must be able to provide written informed consent Exclusion Criteria: * Patients less than 18 years of age * Patients without metastatic castration resistant prostate carcinoma with skeletal, visceral and/or nodal involvement * Inability to lie still for PET scanning * Patients unable to provide written informed consent

What they're measuring

Gallium Ga 68-DOTATATE Uptake

Timeframe: During PET/CT scan, up to 2 hours

Trial details

NCT IDNCT03448458

SponsorEmory University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-02-06

Results submitted2024-03-27

View on ClinicalTrials.gov More Castration-Resistant Prostate Carcinoma trials